Pappas Ventures names Pat Gage to scientific advisory board

Monday, July 9, 2012 04:56 PM

Pappas Ventures, a life sciences investor based in Durham, N.C., has appointed L. Patrick Gage, PhD, to the company's scientific advisory board.

Gage has extensive experience in the biotech and pharmaceutical industry, overseeing the development of more than a dozen marketed biologics and vaccines, as well as several small molecule drugs. During his 18-year career at Hoffmann-La Roche, he held several leadership roles in research management, including service as vice president of exploratory research. Gage then joined Genetics Institute and ultimately served as president after Wyeth (now Pfizer) acquired the company. He was then named president of Wyeth Research, taking responsibility for global pharmaceutical and vaccine R&D, as well as global biopharmaceutical manufacturing.

Gage also founded enGage Biotech Consulting in 2003 to focus on guiding the development of new biopharmaceutical products and companies. In addition to his consulting work, he currently serves as chairman of Cytokinetics and chairman of Tetraphase Pharmaceuticals. He has previously served as chairman for PDL BioPharma and Adnexus Therapeutics.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 22

Roche/Genentech plans pilot trial to measure patientpreference for participating at home v. at study site

Bipartisan 21st Century Cures initiative prepares to draft legislation to accelerate biomedical R&D, lower cost

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

September

Today's fastest, most economical sponsors
Standout sponsors reveal how they shorten regulatory, clinical cycle times

From the trenches: Sites' eye view of state of the industry
CW’s first site focus groups uncover frustration with 'progress,' but a passion for their mission

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

August

Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs